Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.82 |
| ▸ | DRD2 | P14416 | 17/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378773 | 1.00 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL12313316 | 1.00 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL11911831 | 1.00 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL12313318 | 0.90 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL378470 | 0.90 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL11915457 | 0.90 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL11911832 | 0.90 | DRD3 (0.82) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL378312 | 0.90 | DRD3 (1.00) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL396654 | 0.89 | DRD3 (0.98) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL4551573 | 0.89 | DRD3 (0.98) | DRD3KCNH2DRD2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | claimed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| EP-2060570-B1 | Azabicyclo[3.1.0] hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-7855298-B2 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | DRD3 1131/4885KCNH2 4867/4885DRD2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.